.png)
ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
.png)
4336 Plainfield Ave ne Grand Rapids Michigan 49525
16162083711
fitlifehere@gmail.com
Copyright © 2023 fitlife. All Rights Reserved
